urea has been researched along with Depression in 32 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluate pimavanserin treatment for depression in patients with PD." | 9.34 | An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. ( Abler, V; Aldred, JL; Alva, G; Cantillon, M; Coate, B; DeKarske, D; Jacobi, L; Norton, JC; Nunez, R, 2020) |
| "In a post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy." | 9.34 | Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. ( Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2020) |
| "Adjunctive pimavanserin was not associated with an increase in suicidal ideation in patients with MDD." | 9.34 | Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. ( Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2020) |
| "These data indicate that urea accumulation in brain is an independent factor causing depression, bypassing the psychosocial stress." | 7.91 | High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation. ( Chen, D; Chen, Y; Flynn, T; He, Q; Hu, L; Huang, B; Li, J; Li, K; Lian, X; Liang, J; Lin, X; Ran, J; Sands, JM; Shi, J; Sun, J; Tian, K; Wang, H; Wang, K; Wang, W; Xie, Z; Xu, D; Xu, M; Yan, L; Yang, B; Yuan, D; Zhang, Y; Zhao, M; Zhong, D; Zhou, P; Zhou, Z; Zhu, S, 2019) |
| "Depression and type 2 diabetes (T2D) are serious public health problems with irreversible health consequences and a significant economic burden on the healthcare system." | 5.72 | Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study. ( Geng, Y; Li, X; Ma, J; Mao, Y; Zhao, Y; Zhu, S, 2022) |
| "Evaluate pimavanserin treatment for depression in patients with PD." | 5.34 | An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. ( Abler, V; Aldred, JL; Alva, G; Cantillon, M; Coate, B; DeKarske, D; Jacobi, L; Norton, JC; Nunez, R, 2020) |
| "In a post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy." | 5.34 | Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. ( Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2020) |
| "Adjunctive pimavanserin was not associated with an increase in suicidal ideation in patients with MDD." | 5.34 | Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. ( Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2020) |
| "This study was done to evaluate the effect of co-treatment of orexin agents along with citalopram on the modulation of depression-like behavior and the expression of BDNF in the prefrontal cortex (PFC) of sleep-deprived male mice." | 4.12 | Synergistic antidepressant effects of citalopram and SB-334867 in the REM sleep-deprived mice: Possible role of BDNF. ( Alibeik, H; Bananej, M; Khakpai, F; Saadati, N; Zarrindast, MR, 2022) |
| "These data indicate that urea accumulation in brain is an independent factor causing depression, bypassing the psychosocial stress." | 3.91 | High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation. ( Chen, D; Chen, Y; Flynn, T; He, Q; Hu, L; Huang, B; Li, J; Li, K; Lian, X; Liang, J; Lin, X; Ran, J; Sands, JM; Shi, J; Sun, J; Tian, K; Wang, H; Wang, K; Wang, W; Xie, Z; Xu, D; Xu, M; Yan, L; Yang, B; Yuan, D; Zhang, Y; Zhao, M; Zhong, D; Zhou, P; Zhou, Z; Zhu, S, 2019) |
| "In 49 patients receiving continuous ambulatory peritoneal dialysis, we assessed the relative influences of adequacy of dialysis (assessed by kinetic transfer/volume urea) and psychological symptoms (depression and anxiety) upon the patients' evaluation of their overall quality of life (QoL)." | 3.69 | Quality of life in peritoneal dialysis patients. ( Baltimore, D; Finkelstein, FO; Finkelstein, SH; Juergensen, P; Kliger, AS; Steele, TE, 1996) |
| "Depression and type 2 diabetes (T2D) are serious public health problems with irreversible health consequences and a significant economic burden on the healthcare system." | 1.72 | Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study. ( Geng, Y; Li, X; Ma, J; Mao, Y; Zhao, Y; Zhu, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (18.75) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 9 (28.13) | 2.80 |
| Authors | Studies |
|---|---|
| Saadati, N | 1 |
| Bananej, M | 1 |
| Khakpai, F | 2 |
| Zarrindast, MR | 2 |
| Alibeik, H | 1 |
| Shang, Y | 1 |
| Wang, M | 1 |
| Hao, Q | 1 |
| Meng, T | 1 |
| Li, L | 1 |
| Shi, J | 2 |
| Yang, G | 1 |
| Zhang, Z | 1 |
| Yang, K | 1 |
| Wang, J | 1 |
| Mao, Y | 3 |
| Li, X | 4 |
| Zhu, S | 4 |
| Ma, J | 3 |
| Geng, Y | 3 |
| Zhao, Y | 4 |
| Feng, L | 1 |
| Yin, J | 1 |
| Zhang, P | 1 |
| An, J | 1 |
| Song, Q | 1 |
| Ping, P | 1 |
| Fu, S | 1 |
| Wang, H | 1 |
| Huang, B | 1 |
| Wang, W | 1 |
| Li, J | 2 |
| Chen, Y | 1 |
| Flynn, T | 1 |
| Zhao, M | 1 |
| Zhou, Z | 1 |
| Lin, X | 1 |
| Zhang, Y | 1 |
| Xu, M | 1 |
| Li, K | 1 |
| Tian, K | 1 |
| Yuan, D | 1 |
| Zhou, P | 1 |
| Hu, L | 1 |
| Zhong, D | 1 |
| Chen, D | 1 |
| Wang, K | 1 |
| Liang, J | 1 |
| He, Q | 1 |
| Sun, J | 1 |
| Yan, L | 2 |
| Sands, JM | 1 |
| Xie, Z | 1 |
| Lian, X | 1 |
| Xu, D | 1 |
| Ran, J | 2 |
| Yang, B | 2 |
| DeKarske, D | 1 |
| Alva, G | 1 |
| Aldred, JL | 1 |
| Coate, B | 1 |
| Cantillon, M | 1 |
| Jacobi, L | 1 |
| Nunez, R | 1 |
| Norton, JC | 1 |
| Abler, V | 1 |
| Papakostas, GI | 2 |
| Fava, M | 2 |
| Freeman, MP | 2 |
| Shelton, RC | 2 |
| Thase, ME | 2 |
| Jha, MK | 2 |
| Trivedi, MH | 2 |
| Dirks, B | 2 |
| Liu, K | 2 |
| Stankovic, S | 2 |
| Neis, VB | 1 |
| Moretti, M | 1 |
| Rosa, PB | 1 |
| Dalsenter, YO | 1 |
| Werle, I | 1 |
| Platt, N | 1 |
| Kaufmann, FN | 1 |
| Rosado, AF | 1 |
| Besen, MH | 1 |
| Rodrigues, ALS | 1 |
| Gründer, G | 1 |
| Cumming, P | 1 |
| Kumari, N | 1 |
| Agrawal, S | 1 |
| Kumari, R | 1 |
| Sharma, D | 1 |
| Luthra, PM | 1 |
| Hill, R | 1 |
| Disney, A | 1 |
| Conibear, A | 1 |
| Sutcliffe, K | 1 |
| Dewey, W | 1 |
| Husbands, S | 1 |
| Bailey, C | 1 |
| Kelly, E | 1 |
| Henderson, G | 1 |
| Lauriola, M | 1 |
| Mangiacotti, A | 1 |
| D'Onofrio, G | 1 |
| Cascavilla, L | 1 |
| Paris, F | 1 |
| Paroni, G | 1 |
| Seripa, D | 1 |
| Greco, A | 1 |
| Sancarlo, D | 1 |
| Alijanpour, S | 1 |
| Ebrahimi-Ghiri, M | 1 |
| Chai, HH | 1 |
| Fu, XC | 1 |
| Ma, L | 1 |
| Sun, HT | 1 |
| Chen, GZ | 1 |
| Song, MY | 1 |
| Chen, WX | 1 |
| Chen, YS | 1 |
| Tan, MX | 1 |
| Guo, YW | 1 |
| Li, SP | 1 |
| Deats, SP | 1 |
| Adidharma, W | 1 |
| Lonstein, JS | 1 |
| Jia, K | 1 |
| An, L | 1 |
| Wang, F | 1 |
| Shi, L | 1 |
| Ran, X | 1 |
| Wang, X | 1 |
| He, Z | 1 |
| Chen, J | 1 |
| McCann, SM | 1 |
| Daly, J | 1 |
| Kelly, CB | 1 |
| Ide, M | 1 |
| Kadoi, Y | 1 |
| Saito, S | 1 |
| Takahashi, K | 1 |
| Sawano, Y | 1 |
| Miyazaki, M | 1 |
| Shimada, H | 1 |
| Ali, BH | 1 |
| Ziada, A | 1 |
| Al Husseni, I | 1 |
| Beegam, S | 1 |
| Nemmar, A | 1 |
| Scott, MM | 1 |
| Marcus, JN | 1 |
| Pettersen, A | 1 |
| Birnbaum, SG | 1 |
| Mochizuki, T | 1 |
| Scammell, TE | 1 |
| Nestler, EJ | 1 |
| Elmquist, JK | 1 |
| Lutter, M | 1 |
| Zhou, H | 1 |
| Lei, T | 1 |
| Zhou, L | 1 |
| Han, J | 1 |
| Das, S | 1 |
| Patra, AP | 1 |
| Shaha, KK | 1 |
| Sistla, SC | 1 |
| Jena, MK | 1 |
| HARE, RL | 2 |
| HOLCOMB, B | 2 |
| PAGE, OC | 2 |
| STEPHENS, JW | 2 |
| HOZUMI, M | 1 |
| SUGIMURA, T | 1 |
| Graham, MR | 1 |
| Davies, B | 1 |
| Kicman, A | 1 |
| Cowan, D | 1 |
| Hullin, D | 1 |
| Baker, JS | 1 |
| Steele, TE | 1 |
| Baltimore, D | 1 |
| Finkelstein, SH | 1 |
| Juergensen, P | 1 |
| Kliger, AS | 1 |
| Finkelstein, FO | 1 |
| Altieri, P | 1 |
| Sorba, G | 1 |
| Bolasco, P | 1 |
| Asproni, E | 1 |
| Ledebo, I | 1 |
| Cossu, M | 1 |
| Ferrara, R | 1 |
| Ganadu, M | 1 |
| Cadinu, F | 1 |
| Serra, G | 1 |
| Cabiddu, G | 1 |
| Sau, G | 1 |
| Casu, D | 1 |
| Passaghe, M | 1 |
| Bolasco, F | 1 |
| Pistis, R | 1 |
| Ghisu, T | 1 |
| Segers, MJ | 1 |
| Mertens, C | 1 |
| Gray, DJ | 1 |
| Ecanow, B | 1 |
| Gold, BH | 1 |
| Tunkunas, P | 1 |
| Kerry, RJ | 1 |
| Owen, G | 1 |
| Griffiths, H | 1 |
| Randall, ZC | 1 |
| Davies, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression[NCT03482882] | Phase 2 | 47 participants (Actual) | Interventional | 2018-03-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-I is a clinician-rated 7-point scale to rate the improvement in the patient's depression at the time of assessment relative baseline. The CGI-I ranges from 1 (very much improved) to 7 (very much worse) (NCT03482882)
Timeframe: At Week 8
| Intervention | score on a scale (Mean) |
|---|---|
| Pimavanserin Full Analysis Set | 2.0 |
"The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe Depression.~Response was defined as ≥50% reduction from baseline in HAMD-17 total score. Patients without Week-8 score were counted as nonresponders." (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| Pimavanserin Full Analysis Set | 27 |
The CGI-S is a clinician-rated 7-point scale to rate the severity of the patient's depression at the time of assessment. The CGI-S ranges from 1 (normal) to 7 (patient is among the most severely ill). (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline CGI-S | 8 Week CGI-S CFB | |
| Pimavanserin Full Analysis Set | 4.1 | -1.8 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression. (NCT03482882)
Timeframe: 2, 4, and 6 weeks from baseline
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline HAMD-17 total score | Week 2 HAMD-17 total score CFB | Week 4 HAMD-17 total score CFB | Week 6 HAMD-17 total score CFB | |
| Pimavanserin Full Analysis Set | 19.2 | -7.5 | -9.7 | -9.6 |
The SCOPA-NS subscale addresses problems in nighttime sleep and consists of 5 items (sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, early wakening). Each item has 4 response options (ranging from 0=not at all to 3=a lot). The SCOPA-NS score ranges from 0 to 15, with a higher score indicating more severe nighttime sleep problems. (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline SCOPA-NS | Week 8 SCOPA-NS CFB | |
| Pimavanserin Full Analysis Set | 6.1 | -2.1 |
The SCOPA-DS subscale addresses problems in daytime sleepiness and consists of 6 items (falling asleep unexpectedly, falling asleep peacefully, falling asleep watching TV/reading, falling asleep while talking to someone, having difficulty staying awake, whether falling asleep in the daytime is considered a Problem). Each item has 4 response options (from 0=never to 3=often). The SCOPA-DS subscale score ranges from 0 to 18, with a higher score indicating more severe DS problems. (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline SCOPA-DS | 8 Week SCOPA-DS CFB | |
| Pimavanserin Full Analysis Set | 5.2 | -2.2 |
"The EQ-5D-5L is a standardized measure of health status. The questionnaire consists of 2 components: the EQ-5D-5L descriptive system and the EQ-5D-5L Visual Analogue scale (EQ-5D-5L VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (from 1=no problem to 5=extreme Problems). The digits for the 5 dimensions are combined into a 5-digit code that describes the patient's health state, which is then converted into a single summary index value. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility.~The EQ-5D-5L VAS records the patient's health on a vertical visual analogue scale, ranging from 100 (=the best health you can imagine) to 0 (=the worst health you can imagine)." (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline EQ-5D-5L index score | 8 Week EQ-5D-5L index score CFB | Baseline EQ-5D-5L VAS | 8 Week EQ-5D-5L VAS CFB | |
| Pimavanserin Full Analysis Set | 0.6750 | 0.0712 | 63.9 | 6.7 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression. (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline HAMD-17 total score | Week 8 HAMD-17 total score | |
| Pimavanserin Full Analysis Set | 19.2 | 8.1 |
6 trials available for urea and Depression
| Article | Year |
|---|---|
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Topics: Aged; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, | 2020 |
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depression; Depressive Disorder, Major; | 2020 |
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Topics: Adult; Depression; Depressive Disorder, Major; Double-Blind Method; Humans; Piperidines; Suicidal Id | 2020 |
Effects of landiolol on left ventricular function during electroconvulsive therapy: a transthoracic echocardiographic study.
Topics: Adrenergic beta-Antagonists; Aged; Depression; Echocardiography; Electroconvulsive Therapy; Hemodyna | 2010 |
Recombinant human growth hormone in abstinent androgenic-anabolic steroid use: psychological, endocrine and trophic factor effects.
Topics: Adult; Anabolic Agents; Androgens; Anxiety; Blood Glucose; Body Composition; C-Reactive Protein; Dep | 2007 |
Predilution haemofiltration--the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study.
Topics: Blood Flow Velocity; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Depr | 2001 |
26 other studies available for urea and Depression
| Article | Year |
|---|---|
Synergistic antidepressant effects of citalopram and SB-334867 in the REM sleep-deprived mice: Possible role of BDNF.
Topics: Animals; Antidepressive Agents; Benzoxazoles; Brain-Derived Neurotrophic Factor; Citalopram; Depress | 2022 |
Development of indole-2-carbonyl piperazine urea derivatives as selective FAAH inhibitors for efficient treatment of depression and pain.
Topics: Amidohydrolases; Animals; Depression; Endocannabinoids; Enzyme Inhibitors; Heterocyclic Compounds; H | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Physical inability rather than depression and cognitive impairment had negative effect on centenarian prognosis: A prospective study with 5-year follow-up.
Topics: Aged; Aged, 80 and over; Centenarians; Cognitive Dysfunction; Depression; Female; Follow-Up Studies; | 2023 |
High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation.
Topics: Adult; Aged; Animals; Brain; Depression; Disease Models, Animal; Female; Humans; Long-Term Potentiat | 2019 |
The involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Drug Combinations; Female; Glycogen Sy | 2020 |
Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT
Topics: Alzheimer Disease; Animals; Brain; Depression; Disease Models, Animal; Mice; Mice, Transgenic; Pharm | 2021 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprot | 2018 |
The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception.
Topics: Analgesics, Opioid; Animals; Depression; Drug Tolerance; Male; Mice; Mice, Inbred C57BL; Receptors, | 2018 |
Neurocognitive Disorders and Dehydration in Older Patients: Clinical Experience Supports the Hydromolecular Hypothesis of Dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; Chlorides; | 2018 |
Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice.
Topics: Animals; Antidepressive Agents; Benzoxazoles; Depression; Dose-Response Relationship, Drug; Drug The | 2019 |
The chemokine CXCL1 and its receptor CXCR2 contribute to chronic stress-induced depression in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Brain-Derived Neurotrophic Factor; Che | 2019 |
Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazoles; Circadian Rhythm; Depression; Disease Models, Anim | 2014 |
Aggravation of Helicobacter pylori stomach infections in stressed military recruits.
Topics: Adolescent; Antibodies, Bacterial; Breath Tests; Catecholamines; CD4-CD8 Ratio; Complement C3; Compl | 2016 |
The impact of long-term lithium treatment on renal function in an outpatient population.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Creatinine; Cross-Sectional Studies; Depression; Female; | 2008 |
Motor and behavioral changes in rats with adenine-induced chronic renal failure: influence of acacia gum treatment.
Topics: Adenine; Animals; Body Weight; Creatinine; Depression; Drinking; Gum Arabic; Kidney Failure, Chronic | 2011 |
Hcrtr1 and 2 signaling differentially regulates depression-like behaviors.
Topics: Animals; Anxiety; Benzoxazoles; Choice Behavior; Depression; Disease Models, Animal; Immobility Resp | 2011 |
Mice lacking urea transporter UT-B display depression-like behavior.
Topics: Animals; Cerebrovascular Circulation; Crosses, Genetic; Depression; Escape Reaction; Exploratory Beh | 2012 |
High-voltage suicidal electrocution with multiple exit wounds.
Topics: Adult; Alcoholism; Burns, Electric; Creatine Kinase; Creatinine; Depression; Electric Injuries; Fore | 2013 |
Toxicity of carbutamide; report of a fatal case of bone-marrow depression and anuria.
Topics: Anuria; Bone Marrow; Carbutamide; Depression; Sulfanilamide; Sulfanilamides; Urea | 1957 |
Toxicity of carbutamide; report of a fatal case of bone-marrow depression and anuria.
Topics: Anuria; Bone Marrow; Carbutamide; Depression; Sulfanilamide; Sulfanilamides; Urea | 1957 |
Toxicity of carbutamide; report of a fatal case of bone-marrow depression and anuria.
Topics: Anuria; Bone Marrow; Carbutamide; Depression; Sulfanilamide; Sulfanilamides; Urea | 1957 |
Toxicity of carbutamide; report of a fatal case of bone-marrow depression and anuria.
Topics: Anuria; Bone Marrow; Carbutamide; Depression; Sulfanilamide; Sulfanilamides; Urea | 1957 |
Studies on the mechanism of catalase depression by toxohormone, with the aid of allylisopropylacetamide, allylisopropylacetylcarbamide, and 3-amino-1,2,4-triazole.
Topics: Allylisopropylacetamide; Amides; Amitrole; Azoles; Catalase; Depression; Depressive Disorder; Endoto | 1962 |
Quality of life in peritoneal dialysis patients.
Topics: Adult; Aged; Anxiety; Attitude to Health; Depression; Female; Humans; Kidney Failure, Chronic; Male; | 1996 |
Psychological and bioclinical CHD risk factors. Quantitative differences between obese, normal and thin subjects.
Topics: Adult; Anxiety; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Coronary Disease; Depressio | 1974 |
The diagnostic process in general practice illustrated by a case of scurvy.
Topics: Aged; Ascorbic Acid; Blood Sedimentation; Depression; Diazepam; Diet; Ecchymosis; Family Practice; F | 1974 |
Serum albumin and urea during states of anxiety and depression.
Topics: Anxiety; Depression; Humans; Serum Albumin; Urea | 1973 |
Changes in body water, weight and electrolytes in recurrent mental illness.
Topics: Body Weight; Depression; Female; Humans; Male; Mental Disorders; Urea; Water-Electrolyte Balance | 1968 |